Clinical Trials Browser

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

30 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Phase 1 Completed

36 enrolled 16 charts

CNS

Glioblastoma

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Phase 1 Completed

57 enrolled 19 charts

Tumor-Agnostic

Neoplasms

NCT02216617 2017-10-27

TAPIS

Phase 1 Completed

8 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01721525 2017-10-25

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Phase 1 Completed

10 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02020577 2017-06-22

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Phase 1 Completed

58 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1 Completed

83 enrolled 42 charts

Tumor-Agnostic

Neoplasms

NCT00993499 2015-10-07

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Phase 1 Completed

44 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01090011 2015-10-02

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Phase 1 Completed

171 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Phase 1 Completed

70 enrolled 25 charts

Tumor-Agnostic

Neoplasms

NCT02171663 2015-01-28

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

43 enrolled

Tumor-Agnostic

Neoplasms

NCT02171637 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

38 enrolled

Tumor-Agnostic

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms

NCT02171702 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Phase 1 Completed

53 enrolled

Tumor-Agnostic

Neoplasms

NCT02171728 2014-06-24

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

30 enrolled

Tumor-Agnostic

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasms

NCT01169675 2014-06-09

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase 1 Completed

53 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Phase 1 Completed

28 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

BIBW 2992 in Patients With Advanced Solid Tumors

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Safety Study of Afatinib for Brain Cancer

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

TAPIS

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors